An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

This study is currently recruiting participants.
Verified December 2013 by to-BBB technologies B.V.
Sponsor:
Information provided by (Responsible Party):
to-BBB technologies B.V.
ClinicalTrials.gov Identifier:
NCT01386580
First received: June 28, 2011
Last updated: December 16, 2013
Last verified: December 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2014
  Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)